The Lancet Oncology · 2016 · 980 citations · 15 references
MedicineImmunologyOncologyImmunotherapyMolecular OncologyTumor ImmunologyCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmunotherapy For Skin CancerBiomarker-guided Combination ImmunotherapyCombination Checkpoint TherapyDual Checkpoint InhibitionImmune Checkpoint Combination TherapyMelanoma Adjuvant TherapyMelanoma ImmunotherapyMelanoma ProgressionMetastatic Melanoma Treatment
15
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi, Steven O’Day, David F. McDermott et al. · New England Journal of Medicine · 2010 · 15.2K citations · Full text
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2015 · 8.1K citations · Full text
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert, Georgina V. Long, Benjamin Brady et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan et al. · New England Journal of Medicine · 2013 · 4.2K citations · Full text
Medicine, Oncology, Pharmacology +17